Agf Management LTD Alkermes Plc. Transaction History

Agf Management LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$23.21 - $27.24 $519,996 - $610,284	22,404 Added 29.55%	98,230 $2.37 Million
Q1 2024 May 13, 2024	SELL	$26.4 - $32.56 $1.07 Million - $1.32 Million	-40,466 Reduced 34.8%	75,826 $2.05 Million
Q4 2023 Feb 07, 2024	BUY	$23.37 - $28.68 $111,918 - $137,348	4,789 Added 4.29%	116,292 $3.23 Million
Q3 2023 Nov 13, 2023	SELL	$27.17 - $31.97 $160,438 - $188,782	-5,905 Reduced 5.03%	111,503 $3.12 Million
Q2 2023 Aug 09, 2023	SELL	$28.34 - $33.63 $265,970 - $315,617	-9,385 Reduced 7.4%	117,408 $3.67 Million
Q1 2023 May 03, 2023	SELL	$25.31 - $29.02 $370,057 - $424,301	-14,621 Reduced 10.34%	126,793 $3.57 Million
Q4 2022 Feb 14, 2023	BUY	$21.94 - $26.24 $3.1 Million - $3.71 Million	141,414 New	141,414 $0

363

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.72B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Agf Management LTD, based on Form 13F filings with the SEC.

Stay updated on Agf Management LTD with notifications on news.